pd 98059 has been researched along with pioglitazone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Ago, T; Iida, M; Iwase, M; Kitazono, T; Nakamura, U; Ueta, M; Wakisaka, M; Yoshinari, M | 1 |
| Fujii, H; Ishihara, S; Kimura, H; Li, X; Okada, T; Takahashi, N; Torii, K; Yoshida, H | 1 |
| Arens, C; Bader, M; Caglayan, E; Euler, G; Heger, J; Hinrichs, S; Rosenkranz, S; Schlüter, KD; Schreckenberg, R; Wenzel, S | 1 |
| Cao, ZL; Li, Y; Li, ZB; Shen, L; Wang, H; Ye, P; Zhu, QW | 1 |
5 other study(ies) available for pd 98059 and pioglitazone
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose.
Topics: Actins; Angiotensin II; Animals; Aspirin; Cells, Cultured; Cyclooxygenase Inhibitors; DNA, Antisense; Enzyme Inhibitors; Flavonoids; Gene Expression; Glomerular Mesangium; Glucose; Hypoglycemic Agents; Indomethacin; Ligands; Pioglitazone; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Thiazolidinediones; Transcription Factors; Vasoconstrictor Agents | 2004 |
A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.
Topics: Cell Hypoxia; Cells, Cultured; Flavonoids; Genistein; Humans; Inflammation; Kidney Tubules, Proximal; MAP Kinase Kinase 1; Pioglitazone; Plasminogen Activator Inhibitor 1; PPAR gamma; Prostaglandin D2; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2008 |
Controlling cardiomyocyte length: the role of renin and PPAR-{gamma}.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cell Shape; Cells, Cultured; Endothelin-1; Enzyme Activation; Flavonoids; Imidazoles; Mannosephosphates; Mice; Mice, Inbred C3H; Mice, Inbred DBA; Mice, Knockout; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Pioglitazone; PPAR gamma; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Transgenic; Receptor, IGF Type 2; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Renin; Thiazolidinediones; Time Factors | 2011 |
Pioglitazone attenuates myocardial ischemia-reperfusion injury via up-regulation of ERK and COX-2.
Topics: Anilides; Animals; Apoptosis; Blotting, Western; Cyclooxygenase 2; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Male; Myocardial Reperfusion Injury; Phosphorylation; Pioglitazone; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Thiazolidinediones | 2012 |